COMMUNIQUÉS West-GlobeNewswire
-
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
08/10/2026 -
Echosens to Address GLP-1 Costs and Metabolic Health at SIIA National Conference 2026, Highlight Opportunities for Self-Insured Stakeholders and On-Site Clinics
08/10/2026 -
Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies
08/10/2026 -
UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
08/10/2026 -
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
08/10/2026 -
Lakefront Receives Transparency Notification from Bank of America
08/10/2026 -
Sienna Continues Platform Growth in Ontario
08/10/2026 -
Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
08/10/2026 -
Quantum-Si Demonstrates Detection of 19 Amino Acids in Proteus™ Development Program
08/10/2026 -
NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026
08/10/2026 -
Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
08/10/2026 -
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
08/10/2026 -
Rua Bioscience and PharmAla Biotech partner to supply medicinal MDMA in New Zealand
08/10/2026 -
Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
08/10/2026 -
Initiation of buy-back programme
08/10/2026 -
Clever Care Health Plan Achieves 4.5-Star Medicare Advantage Rating from CMS for Star Year 2027
08/10/2026 -
Alignment Healthcare Earns 4 Stars or Higher for Six of Seven Eligible Medicare Advantage Contracts in CMS 2027 Star Ratings
08/10/2026 -
New results across pediatric, adult and real-world insomnia settings highlight the expanding clinical evidence for daridorexant at Sleep Europe 2026
08/10/2026 -
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 30 septembre 2026
08/10/2026
Pages